BridgeMD
New treatment option for End Stage Chronic Renal Failure
Official title Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
ClinicalTrials.gov ID: NCT07491042
What this study is testing
What is Dapagliflozin?
Dapagliflozin is an investigational medicine, given as an once-daily, being studied as a potential treatment for end stage chronic renal failure.
Also referred to as SGLT2i.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This project aims to examine the effects of six-month treatment with selective SGLT2 inhibitor dapagliflozin in patients with end-stage kidney disease on chronic peritoneal dialysis. Methods: A prospective, open label, single-arm interventional clinical trial, will conduct at Nizwa Hospital from March 1st, 2026, to August 31th , 2026, and includes thirty (30) end-stage kidney disease diabetic and non-diabetic patients on chronic peritoneal dialysis, will receive selective SGLT2i Dapagliflozin 10 mg once daily (OD).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 13 and older
You may be able to join if
- o age equal to or more than13 years.
- All genders.
- All patients undergoing chronic Peritoneal Dialysis.
- Urine output equal or more than 150 ml/24 hours.
You likely can't join if
- o Age less than 13 years
- Patients with type I diabetes mellitus.
- Patients with recurrent urinary tract infection (UTI) or peripheral vascular diseases (P.V.D).
- Patients with urine output less than 150 ml/24hours.
- Patients with recurrent hypoglycemic episodes
- Patients with acute or chronic liver disease,
See the full eligibility criteria
- o age equal to or more than13 years.
- All genders.
- All patients undergoing chronic Peritoneal Dialysis.
- Urine output equal or more than 150 ml/24 hours.
- o Age less than 13 years
- Patients with type I diabetes mellitus.
- Patients with recurrent urinary tract infection (UTI) or peripheral vascular diseases (P.V.D).
- Patients with urine output less than 150 ml/24hours.
- Patients with recurrent hypoglycemic episodes
- Patients with acute or chronic liver disease,
- Patients who refuse to participate in the study.
- peritoneal Dialysis catheter (PDC) related peritonitis in last 3 months
The study team makes the final eligibility decision.
Where it's taking place
- Nizwa, Oman
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 13 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nizwa, Oman. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.